

Vita Reta 10mg
- Compound
- Reta
- Strength
- 10 mg per vial
- Pack
- 1 vial
- Total
- 10 mg
- Half-life
- About 6 days
- Form
- Freeze-dried powder
- Ships from inside Canada
- Tracking within 72 hours
- Free Canada Post shipping over $300
- Plain, unbranded box
Vita Reta 10mg in Canada
Reta is an investigational peptide taken once a week. Instead of one receptor, it targets three: GLP-1, GIP and glucagon. It has reached late-stage trials but is not approved anywhere in the world.
What you get: a single vial of 10 mg freeze-dried powder. Dissolve it in bacteriostatic water before use. Priced in Canadian dollars and sent from inside Canada.
Main reason people buy it
- Studying weight loss and metabolic disease
How the triple agonist works
The GLP-1 and GIP parts lower appetite and improve how insulin is released. The glucagon part adds something the others lack: it raises energy use and gets the liver burning more fat. A 48-week phase 2 trial saw average weight loss of about 24% on the top dose.
Half-life: about 6 days.
Clinical reference dose
The phase 2 trials opened at 2 mg once a week, then stepped the dose up every 4 weeks toward a target somewhere between 4–12 mg a week. It has no approval for any purpose.
Mixing: 2 ml of bacteriostatic water added to this 10 mg vial makes a 5 mg per ml solution. On a U-100 insulin syringe, every 10 units (0.1 ml) then holds 0.5 mg.
Trial participants saw their heart rate climb, with bigger rises at higher doses.
The amounts above come from product labels and clinical studies. They are a reference, not a personal recommendation; your doctor sets the dose using your own bloodwork.
Combinations and interactions
Often compared or used with
- Often put next to TZ5 (GLP-1/GIP) and semaglutide (GLP-1) for comparison.
- Incretin peptides should never be combined with one another.
Interactions to know
- Insulin and sulfonylureas: raised chance of low blood sugar.
- Oral medicines: absorption may be altered.
Tell your doctor and pharmacist about everything you use, supplements too, before you start anything new.
Side effects and risks
Stomach effects
Nausea, vomiting and diarrhea, rising with the dose.
Heart rate
A higher resting heart rate.
Unknown long-term safety
It is still being tested in trials.
Injection safety
Always use a new sterile needle and syringe, swab the stopper and your skin with alcohol, and never share. Redness, heat or swelling that is worse after a day or two can be a sign of infection and needs a doctor.
Have a personal or family history of medullary thyroid cancer or MEN 2, have had pancreatitis, have type 1 diabetes, or are pregnant.
In Canada: Reta does not have Health Canada approval for human use. It is sold as a research peptide.
Bloodwork checklist
- A1C and fasting glucose
- Kidney function (creatinine, eGFR)
- Liver panel and lipids
- Lipase if you develop belly pain
- Weight and blood pressure, measured at home
Your family doctor can order the full list. Paid private testing is another route, through labs like LifeLabs or Dynacare. Check again about every 3 months.
Ordering in Canada
- Sent from within Canada, so it never has to clear customs.
- Tracking number inside 72 hours of payment. Weekend orders get packed on Sunday or Monday.
- Canada Post Xpresspost: 2–5 business days to most cities across the country. UPS and FedEx are quicker.
- Free shipping with Canada Post when you spend over $300, and with UPS or FedEx over $1,000.
- Plain packaging, free of product names or branding.
- Interac e-Transfer payment in Canadian dollars, straight from your bank.
Common questions
Is Reta approved anywhere?
No. It is still in phase 3 trials, and it is sold here as a research peptide.
How many 4 mg amounts are in one vial?
The vial holds 10 mg, so it contains two and a half 4 mg amounts (0.8 ml each once mixed with 2 ml).
Is Reta legal in Canada?
Reta does not have Health Canada approval for human use. It is sold as a research peptide.
Sources
- A triple-hormone-receptor agonist for obesity: phase 2 trialJastreboff AM et al. · N Engl J Med · 2023 · PMID 37366315
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptCoskun T et al. · Cell Metab · 2022 · PMID 35985340



